CyberKnife stereotactic radiotherapy for treatment of primary intracranial tumors in dogs

Abstract

Background: Limited data exist about the use, efficacy, and prognostic factors influencing outcome when CyberKnife is used to treat dogs with intracranial neoplasia.Objectives: To determine the prognosis and associated prognostic factors for dogs that were imaged, determined to have primary intracranial tumors, and treated with CyberKnife radiotherapy.Animals: Fifty-nine dogs treated with CyberKnife radiotherapy for primary intracranial tumors.Methods: Retrospective medical record review of cases from January 2010 to June 2016. Data extracted from medical records included signalment, weight, seizure history, tumor location, tumor type (based on imaging), gross tumor volume, planned tumor volume, treatment dates, radiation dose, recurrence, date of death, and cause of death.Results: The median progression-free interval (PFI) was 347 days (range 47 to 1529 days), and the median survival time (MST) was 738 days (range 4 to 2079 days).Tumor location was significantly associated with PFI when comparing cerebrum (median PFI 357 days; range 47-1529 days) versus cerebellum (median PFI 97 days; range 97-168 days) versus brainstem (median PFI 266 days; range 30-1484 days), P = .03. Additionally, the presumed tumor type was significantly associated with MST (P < .001).Conclusions and Clinical Importance: Use of Cyberknife and SRT might improve MST, compared with RT, in dogs with intracranial neoplasia.

Dynamic contrast-enhanced computed tomography perfusion parameters of canine suspected brain tumors at baseline and during radiotherapy might be different depending on tumor location but not associated with survival

“…Brain tumors are a common cause of central neurological signs in dogs and associated with high morbidity (1). Radiotherapy (RT) (with or without surgical excision) or debulking is widely recognized as the treatment of choice, both to alleviate clinical signs and improve survival time (2)(3)(4)(5)(6)(7)(8)(9)(10)(11). The survival advantage of surgery is controversial, and surgery is technically demanding and associated with significant morbidity (12)(13)(14).…”

Solitary intraventricular tumors in dogs and cats treated with radiotherapy alone or combined with ventriculoperitoneal shunts: A retrospective descriptive case series

“…Progression‐free survival was 265 days and 558 days in 2 cats treated with RT and 10 months in 1 cat treated with VPS/RT 11,14 . Tumor size, evolution and outcome for choroid plexus tumors was not mentioned separately in the 1 to 3 dogs included in previous reports of irradiation of different brain tumors 15‐18 . One dog was alive 35 months after stereotactic radiosurgery 18 …”

“…11,14 Tumor size, evolution and outcome for choroid plexus tumors was not mentioned separately in the 1 to 3 dogs included in previous reports of irradiation of different brain tumors. [15][16][17][18] One dog was alive 35 months after stereotactic radiosurgery. 18 Our objective was to describe outcome and complications during and after VPS placement and RT, clinical signs, and tumor evolution in a group of dogs and cats with an imaging diagnosis of presumed intraventricular tumor treated with definitive-intent RT or VPS surgery followed by RT.…”

“… 11 , 14 Tumor size, evolution and outcome for choroid plexus tumors was not mentioned separately in the 1 to 3 dogs included in previous reports of irradiation of different brain tumors. 15 , 16 , 17 , 18 One dog was alive 35 months after stereotactic radiosurgery. 18 …”